{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:44:36Z","timestamp":1793112276280,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Wide-spread implementation of treatment regimens for the radical cure of vivax malaria is hindered by a range of factors. This has resulted in an increase in the relative proportion of vivax malaria and is an important obstacle in the achievement of global malaria elimination by 2030. The main objective of this study was to explore the current policies guiding the treatment plans on vivax malaria, and the factors affecting the implementation of radical cure in South\/South East Asian and Asian Pacific countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a qualitative study among respondents who represented national malaria control programmes (NMCPs) or had a role and influence in the national malaria policies. 33 respondents from 17 countries in South\/South East Asia and Asia Pacific participated in interviews between October 15 and December 15, 2020. Semi-structured interviews were conducted virtually except for two face to face interviews and audio-recorded. Transcribed audio-records underwent thematic analysis using QSR NVivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Policies against vivax malaria were underprioritized, compared with the focus on falciparum malaria and, in particular, drug resistant\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      strains. Despite the familiarity with primaquine (PQ) as the essential treatment to achieve the radical cure, the respondents contested the need for G6PD testing. Optional G6PD testing was reported to have poor adherence. The fear of adverse events led health workers to hesitate prescribing PQ. In countries where G6PD was mandatory, respondents experienced frequent stockouts of G6PD rapid diagnostic kits in peripheral health facilities, which was compounded by a short shelf life of these tests. These challenges were echoed across participating countries to various degrees. Most respondents agreed that a shorter treatment regimen, such as single dose tafenoquine could resolve these problems but mandatory G6PD testing will be needed. The recommendation of shorter regimens including tafenoquine or high dose PQ requires operational evidence demonstrating the robust performance of point of care G6PD tests (biosensors).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There was sparse implementation and low adherence to the radical cure in South\/South East Asian and Asian pacific countries. Shorter treatment regimens with appropriate point of care quantitative G6PD tests may resolve the current challenges. Operational evidence on point of care quantitative G6PD tests that includes the feasibility of integrating such tests into the radical cure regimen are critical to ensure its implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-021-03702-5","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T15:07:04Z","timestamp":1616512024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Rolling out the radical cure for vivax malaria in Asia: a qualitative study among policy makers and stakeholders"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8981-3910","authenticated-orcid":false,"given":"Bipin","family":"Adhikari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Rhahim","family":"Awab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"von Seidlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"3702_CR1","unstructured":"WHO: World Malaria Report 2019. Geneva: World Health Organization; 2019."},{"key":"3702_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"3702_CR3","doi-asserted-by":"publisher","first-page":"e1002745","DOI":"10.1371\/journal.pmed.1002745","volume":"16","author":"L von Seidlein","year":"2019","unstructured":"von Seidlein L, Peto TJ, Landier J, Nguyen TN, Tripura R, Phommasone K, et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: a cluster randomised trial. PLoS Med. 2019;16:e1002745.","journal-title":"PLoS Med"},{"key":"3702_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12936-016-1593-y","volume":"15","author":"B Adhikari","year":"2016","unstructured":"Adhikari B, James N, Newby G, von Seidlein L, White NJ, Day NP, et al. Community engagement and population coverage in mass anti-malarial administrations: a systematic literature review. Malar J. 2016;15:523.","journal-title":"Malar J"},{"key":"3702_CR5","doi-asserted-by":"publisher","first-page":"1366136","DOI":"10.1080\/16549716.2017.1366136","volume":"10","author":"B Adhikari","year":"2017","unstructured":"Adhikari B, Pell C, Phommasone K, Soundala X, Kommarasy P, Pongvongsa T, et al. Elements of effective community engagement: lessons from a targeted malaria elimination study in Lao PDR (Laos). Glob Health Action. 2017;10:1366136.","journal-title":"Glob Health Action"},{"key":"3702_CR6","doi-asserted-by":"publisher","first-page":"e0214280","DOI":"10.1371\/journal.pone.0214280","volume":"14","author":"CL Pell","year":"2019","unstructured":"Pell CL, Adhikari B, Myo Thwin M, Kajeechiwa L, Nosten S, Nosten FH, et al. Community engagement, social context and coverage of mass anti-malarial administration: comparative findings from multi-site research in the Greater Mekong sub-Region. PLoS ONE. 2019;14:e0214280.","journal-title":"PLoS ONE"},{"key":"3702_CR7","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0140-6736(18)30792-X","volume":"391","author":"J Landier","year":"2018","unstructured":"Landier J, Parker DM, Thu AM, Lwin KM, Delmas G, Nosten FH, et al. Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. Lancet. 2018;391:1916\u201326.","journal-title":"Lancet"},{"key":"3702_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12936-019-2666-5","volume":"18","author":"SD Nofal","year":"2019","unstructured":"Nofal SD, Peto TJ, Adhikari B, Tripura R, Callery J, Bui TM, et al. How can interventions that target forest-goers be tailored to accelerate malaria elimination in the Greater Mekong Subregion? A systematic review of the qualitative literature. Malar J. 2019;18:32.","journal-title":"Malar J"},{"key":"3702_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4269\/ajtmh.17-0428","volume":"98","author":"TJ Peto","year":"2018","unstructured":"Peto TJ, Tripura R, Davoeung C, Nguon C, Nou S, Heng C, et al. Reflections on a Community engagement strategy for mass antimalarial drug administration in Cambodia. Am J Trop Med Hyg. 2018;98:100\u20134.","journal-title":"Am J Trop Med Hyg"},{"key":"3702_CR10","doi-asserted-by":"publisher","first-page":"e1002815","DOI":"10.1371\/journal.pmed.1002815","volume":"16","author":"E Kenangalem","year":"2019","unstructured":"Kenangalem E, Poespoprodjo JR, Douglas NM, Burdam FH, Gdeumana K, Chalfein F, et al. Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: a longitudinal surveillance study. PLoS Med. 2019;16:e1002815.","journal-title":"PLoS Med"},{"key":"3702_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1590\/S0074-02762006000300001","volume":"101","author":"JR Coura","year":"2006","unstructured":"Coura JR, Suarez-Mutis M, Ladeia-Andrade S. A new challenge for malaria control in Brazil: asymptomatic Plasmodium infection\u2013a review. Mem Inst Oswaldo Cruz. 2006;101:229\u201337.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"3702_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.pt.2004.02.001","volume":"20","author":"J Sattabongkot","year":"2004","unstructured":"Sattabongkot J, Tsuboi T, Zollner GE, Sirichaisinthop J, Cui L. Plasmodium vivax transmission: chances for control? Trends Parasitol. 2004;20:192\u20138.","journal-title":"Trends Parasitol"},{"key":"3702_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4269\/ajtmh.16-0182","volume":"95","author":"MT White","year":"2016","unstructured":"White MT, Yeung S, Patouillard E, Cibulskis R. Costs and cost-effectiveness of Plasmodium vivax control. Am J Trop Med Hyg. 2016;95:52\u201361.","journal-title":"Am J Trop Med Hyg"},{"key":"3702_CR14","doi-asserted-by":"publisher","first-page":"e43162","DOI":"10.1371\/journal.pone.0043162","volume":"7","author":"RR Abeyasinghe","year":"2012","unstructured":"Abeyasinghe RR, Galappaththy GN, Smith Gueye C, Kahn JG, Feachem RG. Malaria control and elimination in Sri Lanka: documenting progress and success factors in a conflict setting. PLoS ONE. 2012;7:e43162.","journal-title":"PLoS ONE"},{"key":"3702_CR15","doi-asserted-by":"crossref","unstructured":"Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the era of the shrinking P. falciparum map. Trends Parasitol. 2020;36:560\u201370.","DOI":"10.1016\/j.pt.2020.03.009"},{"key":"3702_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4269\/ajtmh.16-0141","volume":"95","author":"RE Howes","year":"2016","unstructured":"Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, et al. Global epidemiology of Plasmodium vivax. Am J Trop Med Hyg. 2016;95:15\u201334.","journal-title":"Am J Trop Med Hyg"},{"key":"3702_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/1475-2875-11-280","volume":"11","author":"GK John","year":"2012","unstructured":"John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012;11:280.","journal-title":"Malar J"},{"key":"3702_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12936-018-2380-8","volume":"17","author":"K Thriemer","year":"2018","unstructured":"Thriemer K, Bobogare A, Ley B, Gudo CS, Alam MS, Anstey NM, et al. Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group. Malar J. 2018;17:241.","journal-title":"Malar J"},{"key":"3702_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(19)31285-1","volume":"394","author":"WRJ Taylor","year":"2019","unstructured":"Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394:929\u201338.","journal-title":"Lancet"},{"key":"3702_CR20","doi-asserted-by":"publisher","first-page":"e0169930","DOI":"10.1371\/journal.pone.0169930","volume":"12","author":"B Ley","year":"2017","unstructured":"Ley B, Alam MS, O\u2019Donnell JJ, Hossain MS, Kibria MG, Jahan N, et al. A Comparison of three quantitative methods to estimate G6PD activity in the Chittagong Hill tracts. Bangladesh PLoS One. 2017;12:e0169930.","journal-title":"Bangladesh PLoS One"},{"key":"3702_CR21","doi-asserted-by":"publisher","first-page":"e1814","DOI":"10.1371\/journal.pntd.0001814","volume":"6","author":"PW Gething","year":"2012","unstructured":"Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012;6:e1814.","journal-title":"PLoS Negl Trop Dis"},{"key":"3702_CR22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/infdis\/jiz126","volume":"220","author":"KR Rijal","year":"2019","unstructured":"Rijal KR, Adhikari B, Ghimire P, Banjara MR, Das Thakur G, Hanboonkunupakarn B, et al. Efficacy of primaquine in preventing short- and long-latency Plasmodium vivax relapses in Nepal. J Infect Dis. 2019;220:448\u201356.","journal-title":"J Infect Dis"},{"key":"3702_CR23","doi-asserted-by":"crossref","unstructured":"Robinson LJ, Wampfler R, Betuela I, Karl S, White MT, Li Wai Suen CS, et al. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. PLoS Med. 2015;12:e1001891.","DOI":"10.1371\/journal.pmed.1001891"},{"key":"3702_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12936-017-1784-1","volume":"16","author":"K Thriemer","year":"2017","unstructured":"Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, et al. Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malar J. 2017;16:141.","journal-title":"Malar J"},{"key":"3702_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Quality Health Care. 2007;19:349\u201357.","journal-title":"Int J Quality Health Care"},{"key":"3702_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4300\/JGME-D-11-00307.1","volume":"4","author":"J Sargeant","year":"2012","unstructured":"Sargeant J. Qualitative research Part II: participants, analysis, and quality assurance. J Grad Med Educ. 2012;4:1\u20133.","journal-title":"J Grad Med Educ"},{"key":"3702_CR27","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","volume":"52","author":"B Saunders","year":"2018","unstructured":"Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52:1893\u2013907.","journal-title":"Qual Quant"},{"key":"3702_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s12936-015-0896-8","volume":"14","author":"B Ley","year":"2015","unstructured":"Ley B, Luter N, Espino FE, Devine A, Kalnoky M, Lubell Y, et al. The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malar J. 2015;14:377.","journal-title":"Malar J"},{"key":"3702_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12936-017-1981-y","volume":"16","author":"B Ley","year":"2017","unstructured":"Ley B, Thriemer K, Jaswal J, Poirot E, Alam MS, Phru CS, et al. Barriers to routine G6PD testing prior to treatment with primaquine. Malar J. 2017;16:329.","journal-title":"Malar J"},{"key":"3702_CR30","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1179\/2047772413Z.000000000179","volume":"107","author":"KJ Baird","year":"2013","unstructured":"Baird KJ. Malaria caused by Plasmodium vivax: recurrent, difficult to treat, disabling, and threatening to life\u2013the infectious bite preempts these hazards. Pathog Glob Health. 2013;107:475\u20139.","journal-title":"Pathog Glob Health"},{"issue":"Suppl 1","key":"3702_CR31","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1186\/1475-2875-7-S1-S9","volume":"7","author":"MR Galinski","year":"2008","unstructured":"Galinski MR, Barnwell JW. Plasmodium vivax: who cares? Malar J. 2008;7(Suppl 1):S9.","journal-title":"Malar J"},{"key":"3702_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4269\/ajtmh.2007.77.79","volume":"7","author":"RN Price","year":"2007","unstructured":"Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007;7:79\u201387.","journal-title":"Am J Trop Med Hyg"},{"key":"3702_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.pt.2007.08.011","volume":"23","author":"JK Baird","year":"2007","unstructured":"Baird JK. Neglect of Plasmodium vivax malaria. Trends Parasitol. 2007;23:533\u20139.","journal-title":"Trends Parasitol"},{"key":"3702_CR34","doi-asserted-by":"publisher","first-page":"e0006230","DOI":"10.1371\/journal.pntd.0006230","volume":"12","author":"J Recht","year":"2018","unstructured":"Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis. 2018;12:e0006230.","journal-title":"PLoS Negl Trop Dis"},{"key":"3702_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1179\/2047773215Y.0000000016","volume":"09","author":"JK Baird","year":"2015","unstructured":"Baird JK. Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. Pathog Glob Health. 2015;09:93\u2013106.","journal-title":"Pathog Glob Health"},{"key":"3702_CR36","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S1473-3099(09)70177-X","volume":"9","author":"I Mueller","year":"2009","unstructured":"Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009;9:555\u201366.","journal-title":"Lancet Infect Dis"},{"key":"3702_CR37","unstructured":"WHO. Control and elimination of Plasmodium vivax malaria: a technical brief. Geneva: World Health Organization, 2015. Available online at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/181162\/9789241509244_eng.pdf?sequence=1 (Accessed on 16th December 2020)."},{"key":"3702_CR38","doi-asserted-by":"publisher","first-page":"e1160","DOI":"10.1371\/journal.pntd.0001160","volume":"5","author":"JM Carlton","year":"2011","unstructured":"Carlton JM, Sina BJ, Adams JH. Why is Plasmodium vivax a neglected tropical disease? PLoS Negl Trop Dis. 2011;5:e1160.","journal-title":"PLoS Negl Trop Dis"},{"key":"3702_CR39","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1038\/s41467-019-09991-4","volume":"10","author":"E Maskin","year":"2019","unstructured":"Maskin E, Monga C, Thuilliez J, Berthelemy JC. The economics of malaria control in an age of declining aid. Nat Commun. 2019;10:2269.","journal-title":"Nat Commun"},{"key":"3702_CR40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12936-017-1890-0","volume":"16","author":"R Shretta","year":"2017","unstructured":"Shretta R, Zelman B, Birger ML, Haakenstad A, Singh L, Liu Y, et al. Tracking development assistance and government health expenditures for 35 malaria-eliminating countries: 1990\u20132017. Malar J. 2017;16:251.","journal-title":"Malar J"},{"key":"3702_CR41","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/inthealth\/ihy079","volume":"11","author":"N Kaehler","year":"2019","unstructured":"Kaehler N, Adhikari B, Cheah PY, Day NPJ, Paris DH, Tanner M, et al. The promise, problems and pitfalls of mass drug administration for malaria elimination: a qualitative study with scientists and policymakers. Int Health. 2019;11:166\u201376.","journal-title":"Int Health"},{"key":"3702_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12936-019-2835-6","volume":"18","author":"N Kaehler","year":"2019","unstructured":"Kaehler N, Adhikari B, Cheah PY, von Seidlein L, Day NPJ, Paris DH, et al. Prospects and strategies for malaria elimination in the Greater Mekong Sub-region: a qualitative study. Malar J. 2019;18:203.","journal-title":"Malar J"},{"key":"3702_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4269\/ajtmh.16-0171","volume":"95","author":"JK Baird","year":"2016","unstructured":"Baird JK, Valecha N, Duparc S, White NJ, Price RN. Diagnosis and treatment of Plasmodium vivax malaria. Am J Trop Med Hyg. 2016;95:35\u201351.","journal-title":"Am J Trop Med Hyg"},{"key":"3702_CR44","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/QCO.0b013e32834c61e3","volume":"24","author":"RN Price","year":"2011","unstructured":"Price RN, Douglas NM, Anstey NM, von Seidlein L. Plasmodium vivax treatments: what are we looking for? Curr Opin Infect Dis. 2011;24:578\u201385.","journal-title":"Curr Opin Infect Dis"},{"key":"3702_CR45","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14787210.2016.1220304","volume":"14","author":"CS Chu","year":"2016","unstructured":"Chu CS, White NJ. Management of relapsing Plasmodium vivax malaria. Expert Rev Anti Infect Ther. 2016;14:885\u2013900.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"3702_CR46","doi-asserted-by":"crossref","unstructured":"Galappaththy GN, Tharyan P, Kirubakaran R. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. Cochrane Database Syst Rev. 2013:CD004389.","DOI":"10.1002\/14651858.CD004389.pub3"},{"key":"3702_CR47","unstructured":"WHO. Point-of-care G6PD testing to support safe use of primaquine for the treatment of vivax malaria. Evidence Review Group meeting report Malaria Policy Advisory Committee Meeting, Geneva: World Health Organization, 2015. Available online at: https:\/\/www.who.int\/malaria\/mpac\/mpac-march2015-erg-g6pd.pdf?ua=1 (Accessed on 16th December 2020)."},{"key":"3702_CR48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12916-015-0531-0","volume":"13","author":"JK Baird","year":"2015","unstructured":"Baird JK. Point-of-care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency. BMC Med. 2015;13:296.","journal-title":"BMC Med"},{"key":"3702_CR49","unstructured":"WHO. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale: Policy brief. Geneva: World Health Organization, 2016."},{"key":"3702_CR50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12936-019-2715-0","volume":"18","author":"KIC Ong","year":"2019","unstructured":"Ong KIC, Iwagami M, Araki H, Khattignavong P, Soundala P, Keomalaphet S, et al. Prevalence of G6PD Viangchan variant in malaria endemic areas in Lao PDR: an implication for malaria elimination by 2030. Malar J. 2019;18:75.","journal-title":"Malar J"},{"key":"3702_CR51","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S0140-6736(19)31605-8","volume":"394","author":"PJ Rosenthal","year":"2019","unstructured":"Rosenthal PJ. A shorter course for anti-relapse therapy against vivax malaria. Lancet. 2019;394:898\u2013900.","journal-title":"Lancet"},{"key":"3702_CR52","doi-asserted-by":"publisher","first-page":"e1002224","DOI":"10.1371\/journal.pmed.1002224","volume":"14","author":"CS Chu","year":"2017","unstructured":"Chu CS, Bancone G, Moore KA, Win HH, Thitipanawan N, Po C, et al. Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens. PLoS Med. 2017;14:e1002224.","journal-title":"PLoS Med"},{"key":"3702_CR53","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12936-018-2564-2","volume":"17","author":"S Avalos","year":"2018","unstructured":"Avalos S, Mejia RE, Banegas E, Salinas C, Gutierrez L, Fajardo M, et al. G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients. Malar J. 2018;17:415.","journal-title":"Malar J"},{"key":"3702_CR54","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1056\/NEJMe1816383","volume":"380","author":"NJ White","year":"2019","unstructured":"White NJ. Tafenoquine - A radical improvement? N Engl J Med. 2019;380:285\u20136.","journal-title":"N Engl J Med"},{"key":"3702_CR55","doi-asserted-by":"publisher","first-page":"e0196716","DOI":"10.1371\/journal.pone.0196716","volume":"13","author":"G Bancone","year":"2018","unstructured":"Bancone G, Gornsawun G, Chu CS, Porn P, Pal S, Bansil P, et al. Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood. PLoS ONE. 2018;13:e0196716.","journal-title":"PLoS ONE"},{"key":"3702_CR56","unstructured":"Ruwanpura VSH, Nowak S, Gerth\u2010Guyette E, Theodora M, Dysoley L, Haile M, et al. Further evidence needed to change policy for the safe and effective radical cure of vivax malaria: Insights from the 2019 annual APMEN Vivax Working Group meeting. Asia & the Pacific Policy Studies."},{"key":"3702_CR57","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/1475-2875-13-345","volume":"13","author":"J Nabyonga-Orem","year":"2014","unstructured":"Nabyonga-Orem J, Ssengooba F, Macq J, Criel B. Malaria treatment policy change in Uganda: what role did evidence play? Malar J. 2014;13:345.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03702-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12936-021-03702-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03702-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T16:06:08Z","timestamp":1616515568000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03702-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3702"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03702-5","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"7 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has obtained an ethical approval from University of Oxford Tropical Medicine Research Ethics Committee (OxTREC Reference: 557\u201320), United Kingdom, UK. An oral informed consent was audio-recorded with each participant before the interviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}